, Encore un fois, nous n'avons pas retrouvé de différence significative pour cette variable (p=0, vol.94

, Annexe 1 : Classification d'évolution des stades de la maladie rénale chronique, Source, issue.98

, Guide Parcours de Soins

Y. Ragbaoui, C. Chehbouni, A. E. Hammiri, and R. Habbal, Epidémiologie de l'association fibrillation atriale et insuffisance cardiaque, Pan Afr Med J, vol.26, 2017.

O. Hanon, P. Assayag, J. Belmin, J. P. Collet, J. P. Emeriau et al., Consensus d'experts de la Société française de gériatrie et gérontologie et de la Société française de cardiologie, sur la prise en charge de la fibrillation atriale du sujet âgé, Gériatrie Psychol Neuropsychiatr Vieil, vol.11, issue.2, pp.117-160, 2013.

P. A. Wolf, R. D. Abbott, and W. B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.983-991, 1991.

M. Haïssaguerre, P. Jaïs, D. C. Shah, A. Takahashi, M. Hocini et al., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, vol.339, issue.10, pp.659-66, 1998.

S. Stewart, C. L. Hart, D. J. Hole, and J. Mcmurray, A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study, Am J Med, vol.113, issue.5, pp.359-64, 2002.

P. A. Wolf, T. R. Dawber, H. E. Thomas, and W. B. Kannel, Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study, Neurology, vol.28, issue.10, pp.973-980, 1978.

S. H. Hohnloser, D. Pajitnev, J. Pogue, J. S. Healey, M. A. Pfeffer et al., Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy, J Am Coll Cardiol, vol.50, issue.22, pp.2156-61, 2007.

M. Baroudi, A. Keta, P. Meyer, H. Burri, D. Shah et al., , 2010.

A. Kishore, A. Vail, A. Majid, J. Dawson, K. R. Lees et al., Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and metaanalysis, Stroke, vol.45, issue.2, pp.520-526, 2014.

K. M. Henriksson, B. Farahmand, S. Åsberg, N. Edvardsson, and A. Terént, Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke, Int J Stroke Off J Int Stroke Soc, vol.7, issue.4, pp.276-81, 2012.

M. Grond, M. Jauss, G. Hamann, E. Stark, R. Veltkamp et al., Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study, Stroke, vol.44, issue.12, pp.3357-64, 2013.

, Score de CHADS2 : évaluation du risque d'accident embolique cérébral chez un patient en fibrillation atriale

W. Fmc-dinan.-;-zhu, Q. Xiong, and K. Hong, Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation, Tex Heart Inst J, vol.42, issue.1, pp.6-15, 2015.

V. Jacobs, H. T. May, T. L. Bair, B. G. Crandall, M. Cutler et al., The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation, Heart Rhythm, vol.12, issue.4, pp.681-687, 2015.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, vol.37, issue.38, pp.2893-962, 2016.

J. C. Hsu, P. S. Chan, F. Tang, T. M. Maddox, and G. M. Marcus, Oral Anticoagulant Use in Atrial Fibrillation Patients with a Low Risk of Thromboembolism: Insights from the NCDR® PINNACLE Registry, JAMA Intern Med, vol.175, issue.6, pp.1062-1067, 2015.

R. Nieuwlaat, M. H. Prins, L. Heuzey, J. Vardas, P. E. Aliot et al., Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation, Eur Heart J, vol.29, issue.9, pp.1181-1190, 2008.

J. Ball, M. J. Carrington, S. Stewart, and . Safety, Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management?, Heart Br Card Soc, vol.99, issue.8, pp.542-549, 2013.

I. Marzona, M. O'donnell, K. Teo, P. Gao, C. Anderson et al., Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies, CMAJ Can Med Assoc J, vol.184, issue.6, pp.329-365, 2012.

A. Von-eisenhart-rothe, F. Hutt, J. Baumert, G. Breithardt, A. Goette et al., Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis--data from the German Competence Network on Atrial Fibrillation, EP Europace, vol.17, issue.9, pp.1354-62, 2015.

M. A. Creager, Results of the CAPRIE trial: efficacy and safety of clopidogrel

, Clopidogrel versus aspirin in patients at risk of ischemic events, Vasc Med Lond Engl, vol.3, issue.3, pp.257-60, 1998.

J. Mant, F. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, Lancet Lond Engl, vol.370, issue.9586, pp.493-503, 2007.

C. L. Garwood, T. Corbett, S. Connolly, J. Pogue, R. Hart et al., Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, ACTIVE Writing Group of the ACTIVE Investigators, vol.42, pp.1903-1915, 2006.

R. G. Hart, L. A. Pearce, and M. I. Aguilar, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, vol.146, issue.12, pp.857-67, 2007.

, Traitement par antivitamines K (AVK) : nouvelles informations, 2018.

M. Plichart, G. Berrut, N. Maubourguet, C. Jeandel, J. Emeriau et al., Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG), Drugs Aging, vol.30, issue.12, pp.1019-1047, 2013.

S. Apostolakis, R. M. Sullivan, B. Olshansky, and G. Lip, Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT?R? score, Chest, vol.144, issue.5, pp.1555-63, 2013.

E. M. Hylek and D. E. Singer, Risk factors for intracranial hemorrhage in outpatients taking warfarin, Ann Intern Med, vol.120, issue.11, pp.897-902, 1994.

P. Pouyanne, F. Haramburu, J. L. Imbs, and B. Bégaud, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.

N. S. Vidal--traitement-par-avk--a-savoir-;-roskell, M. Samuel, H. Noack, and B. U. Monz, Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card, Cell Electrophysiol Eur Soc Cardiol, vol.15, issue.6, pp.787-97, 2013.

H. Autorité-de-santé, Prise en charge des surdosages en antivitamines K, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier, 2008.

R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De-vos, H. Crijns et al., A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, vol.138, issue.5, pp.1093-100, 2010.

M. Torn, W. Bollen, F. Van-der-meer, E. E. Van-der-wall, and F. R. Rosendaal, Risks of oral anticoagulant therapy with increasing age, Arch Intern Med, vol.165, issue.13, pp.1527-1559, 2005.

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, issue.12, pp.1139-51, 2009.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, vol.365, issue.10, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

C. B. Granger, J. H. Alexander, J. Mcmurray, R. D. Lopes, E. M. Hylek et al., Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, issue.11, pp.981-92, 2011.

S. J. Connolly, J. Eikelboom, C. Joyner, H. Diener, R. Hart et al., Apixaban in patients with atrial fibrillation, N Engl J Med, vol.364, issue.9, pp.806-823, 2011.

C. S. Miller, S. M. Grandi, A. Shimony, K. B. Filion, and M. J. Eisenberg, Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation, Am J Cardiol, vol.110, issue.3, pp.453-60, 2012.

C. T. Ruff, R. P. Giugliano, E. Braunwald, E. B. Hoffman, N. Deenadayalu et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet Lond Engl, vol.383, issue.9921, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

R. P. Giugliano, C. T. Ruff, E. Braunwald, S. A. Murphy, S. D. Wiviott et al., Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.369, issue.22, pp.2093-104, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00934699

. Haute-autorité-de-santé and . Idarucizumab, Commission de la transparence, 2016.

D. Sur,

H. Autorité-de-santé, Rapport d'évaluation des médicaments anticoagulants oraux. Commission de transparence, 2018.

J. Doucet, E. Greboval-furstenfeld, and A. Tavildari, Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly, Fundam Clin Pharmacol, vol.22, p.3932, 2008.

M. Hawkes, Anticoagulation for atrial fibrillation after intracranial hemorrhage A systematic review, Neurol Clin Pract Print, vol.8, 2018.

M. E. Tinetti, Preventing falls in elderly persons, N Engl J Med, vol.348, issue.1, pp.42-51, 2003.

A. J. Bond, F. J. Molnar, M. Li, M. Mackey, and M. Man-son-hing, The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy, Thromb J, vol.118, pp.612-619, 2005.

M. Man-son-hing, N. G. Lau, A. Laupacis, and A. , Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls, Arch Intern Med, vol.159, issue.7, pp.677-85, 1999.

D. Poli, E. Antonucci, S. Testa, A. Tosetto, W. Ageno et al., Bleeding risk in very old patients on vitamin K antagonist treatment clinical perspective: results of a prospective collaborative study on elderly patients followed by italian centres for anticoagulation, Circulation, vol.124, issue.7, pp.824-833, 2011.

G. Mendelson and W. S. Aronow, Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke, J Am Geriatr Soc, vol.46, issue.11, pp.1423-1427, 1998.

V. Siguret, C. Esquirol, M. Debray, I. Gouin, J. Andreux et al., Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey, Presse Medicale Paris, vol.32, issue.21, pp.972-979, 2003.

R. Charnigo, P. Khairy, J. Guo, A. Shohoudi, and C. S. Elayi, Use of digoxin in atrial fibrillation: One step further in the mortality controversy from the AFFIRM study, Pacing Clin Electrophysiol PACE, 2018.

O. Paziaud, O. Piot, J. Rousseau, X. Copie, T. Lavergne et al., Cardioversion électrique externe des troubles du rythme atriaux : critères prédictifs de succès, 2002.

D. Sur,

D. J. Wilber, C. Pappone, P. Neuzil, D. Paola, A. Marchlinski et al., Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial, JAMA, vol.303, issue.4, pp.333-373, 2010.

H. Calkins, M. R. Reynolds, P. Spector, M. Sondhi, Y. Xu et al., Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses, Circ Arrhythm Electrophysiol, vol.2, issue.4, p.4549, 2009.

R. Cappato, H. Calkins, S. Chen, W. Davies, Y. Iesaka et al., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation, Circ Arrhythm Electrophysiol, vol.3, issue.1, pp.32-40, 2010.

L. Mont, F. Bisbal, A. Hernández-madrid, N. Pérez-castellano, X. Viñolas et al., Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study), Eur Heart J, vol.35, issue.8, pp.501-508, 2014.

N. F. Marrouche, J. Brachmann, D. Andresen, J. Siebels, L. Boersma et al.,

, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, vol.378, issue.5, pp.417-444, 2018.

S. H. Hohnloser, K. H. Kuck, and J. Lilienthal, Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial, Lancet Lond Engl, vol.356, issue.9244, pp.1789-94, 2000.

D. G. Wyse, A. L. Waldo, J. P. Dimarco, M. J. Domanski, Y. Rosenberg et al., A comparison of rate control and rhythm control in patients with atrial fibrillation, N Engl J Med, vol.347, issue.23, pp.1825-1858, 2002.

A. M. Gillinov, E. Bagiella, A. J. Moskowitz, J. M. Raiten, M. A. Groh et al.,

, Rate control versus rhythm control for atrial fibrillation after cardiac surgery, N Engl J Med, vol.374, issue.20, pp.1911-1932, 2016.

I. C. Van-gelder, H. F. Groenveld, H. Crijns, Y. S. Tuininga, J. Tijssen et al., Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, vol.362, issue.15, pp.1363-73, 2010.

M. Rienstra, A. H. Hobbelt, M. Alings, J. Tijssen, M. D. Smit et al., Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial, Eur Heart J, 2018.

E. Teiger, J. Thambo, P. Defaye, J. Hermida, A. S. Klug et al., Percutaneous left atrial appendage closure is a reasonable option for patients with atrial fibrillation at high risk for cerebrovascular events, Circ Cardiovasc Interv, vol.11, issue.3, p.5841, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01788824

J. Saw, J. P. Lopes, M. Reisman, P. Mclaughlin, S. Nicolau et al., Cardiac computed tomography angiography for left atrial appendage closure, Can J Cardiol, vol.32, issue.8, pp.1033-1034, 2016.

D. Biase, L. Santangeli, P. Anselmino, M. Mohanty, P. Salvetti et al., Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study, J Am Coll Cardiol, vol.60, issue.6, pp.531-539, 2012.

A. J. Camm, G. Lip, D. Caterina, R. Savelieva, I. Atar et al., , 2012.

, Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, vol.14, pp.1385-413, 2012.

, Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism | Guidance and guidelines | NICE

D. Sur,

. Haute-autorité-de-santé, Évaluation de l'occlusion de l'appendice auriculaire gauche par voie transcutanée, 2014.

A. Akinapelli, O. Bansal, J. P. Chen, A. Pflugfelder, N. Gordon et al., Left Atrial Appendage Closure -The WATCHMAN Device, Curr Cardiol Rev, vol.11, issue.4, pp.334-374, 2015.

L. Boersma, B. Schmidt, T. R. Betts, H. Sievert, C. Tamburino et al., Implant success and safety of left atrial appendage closure with the WATCHMAN device: periprocedural outcomes from the EWOLUTION registry, Eur Heart J, vol.37, issue.31, pp.2465-74, 2016.

S. H. Ostermayer, M. Reisman, P. H. Kramer, R. V. Matthews, W. A. Gray et al.,

, Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multicenter feasibility trials, J Am Coll Cardiol, vol.46, issue.1, pp.9-14, 2005.

F. Amplatzer-médical, Amplatzer Cardiac Plug et fermeture percutanée de l'auricule gauche, 2009.

P. C. Block, S. Burstein, P. N. Casale, P. H. Kramer, P. Teirstein et al.,

, Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study, JACC Cardiovasc Interv, vol.2, issue.7, pp.594-600, 2009.

D. R. Holmes, V. Y. Reddy, Z. G. Turi, S. K. Doshi, H. Sievert et al.,

, Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial, Lancet Lond Engl, vol.374, issue.9689, pp.534-576, 2009.

V. Y. Reddy, D. Holmes, S. K. Doshi, P. Neuzil, and S. Kar, Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry, Circulation, vol.123, issue.4, pp.417-441, 2011.

V. Y. Reddy, S. Möbius-winkler, M. A. Miller, P. Neuzil, G. Schuler et al., Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology), J Am Coll Cardiol, vol.61, issue.25, pp.2551-2557, 2013.

D. R. Holmes, S. Kar, M. J. Price, B. Whisenant, H. Sievert et al., Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial, J Am Coll Cardiol, vol.64, issue.1, pp.1-12, 2014.

V. Y. Reddy, S. K. Doshi, H. Sievert, M. Buchbinder, P. Neuzil et al., Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation), Trial. Circulation, vol.127, issue.6, pp.720-729, 2013.

D. R. Holmes, S. K. Doshi, S. Kar, M. J. Price, J. M. Sanchez et al., Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis, J Am Coll Cardiol, vol.65, issue.24, pp.2614-2637, 2015.

J. Park, A. Bethencourt, H. Sievert, G. Santoro, B. Meier et al., Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience, Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv, vol.77, issue.5, pp.700-706, 2011.

M. Urena, J. Rodés-cabau, X. Freixa, J. Saw, J. G. Webb et al., Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy, J Am Coll Cardiol, vol.62, issue.2, pp.96-102, 2013.

I. Cruz-gonzalez, M. Fuertes-barahona, J. C. Moreno-samos, R. Gonzalez-ferreiro, Y. Y. Lam et al., Left Atrial Appendage Occlusion: The Current Device Landscape and Future Perspectives, Interv Cardiol Clin, vol.7, issue.2, pp.253-65, 2018.

S. Sahay, L. Nombela-franco, J. Rodes-cabau, P. Jimenez-quevedo, P. Salinas et al., Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials, Heart Br Card Soc, vol.103, issue.2, pp.139-186, 2017.

C. Yerasi, M. Lazkani, P. Kolluru, V. Miryala, J. Kim et al., An updated systematic review and meta-analysis of early outcomes after left atrial appendage occlusion, J Intervent Cardiol, vol.31, issue.2, pp.197-206, 2018.

J. Kefer, A. Aminian, P. Vermeersch, T. De-potter, F. Stammen et al., Transcatheter left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: results from the Belgian registry, EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol, vol.13, issue.13, pp.1603-1614, 2018.

M. Szyma?a, W. Streb, K. Mitr?ga, T. Podolecki, G. Mencel et al.,

, Percutaneous left atrial appendage occlusion procedures in patients with heart failure, Kardiol Pol, vol.75, issue.9, pp.868-76, 2017.

A. Chanda and J. P. Reilly, Left Atrial Appendage Occlusion for Stroke Prevention, Prog Cardiovasc Dis, vol.59, issue.6, pp.626-661, 2017.

T. Dar, M. R. Afzal, B. Yarlagadda, S. Kutty, Q. Shang et al., Mechanical function of the left atrium is improved with epicardial ligation of the left atrial appendage: Insights from the LAFIT-LARIAT Registry, Heart Rhythm, 2018.

Z. Jalal, X. Iriart, M. Dinet, J. Selly, N. Tafer et al., Extending percutaneous left atrial appendage closure indications using the AMPLATZER TM Cardiac Plug device in patients with persistent left atrial appendage thrombus: The thrombus trapping technique, Arch Cardiovasc Dis, vol.109, issue.12, pp.659-66, 2016.

A. M. Gillinov, A. C. Gelijns, M. K. Parides, J. J. Derose, A. J. Moskowitz et al., Surgical ablation of atrial fibrillation during mitral-valve surgery, N Engl J Med, vol.372, issue.15, pp.1399-409, 2015.

R. Whitlock, J. Healey, J. Vincent, K. Brady, K. Teoh et al., Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III, Ann Cardiothorac Surg, vol.3, issue.1, pp.45-54, 2014.

H. Autorité-de-santé, Synthèse des recommandations professionnelles : stratégie de prise en charge en cas de dénutrition protéino-énergétique chez la personne âgée

D. Sur,

C. Haute-autorité-de-santé-;-cordonnier, N. Sprigg, E. C. Sandset, A. Pavlovic, K. S. Sunnerhagen et al., Guide du parcours de soins: Maladie rénale chronique de l'adulte, Nat Rev Neurol, vol.13, issue.9, pp.521-553, 2017.

, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses